Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Mesa, AZ
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Tempe, AZ
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Tucson, AZ
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Stratford, CT
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Stratford, CT
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Clearwater, FL
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Coral Gables, FL
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Orlando, FL
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Pembroke Pines, FL
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Wichita, KA
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Rockville, MD
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Rochester, MN
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Kansas City, MO
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
St. Louis, MO
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Endwell, NY
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Endwell, NY
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Rochester, NY
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Cary, NC
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Cary, NC
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Raleigh, NC
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Downington, PA
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Downington, PA
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Erie, PA
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Erie, PA
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Warwick, RI
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Plano, TX
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
West Jordan, UT
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Norfolk, VA
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Richmond, VA
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Marshfield, WI
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Marshfield, WI
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Tuscaloosa, AL
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Tucson, AZ
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Little Rock, AR
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
mi
from
Atascadero, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
mi
from
Atascadero, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Fresno, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Paramount, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Paramount, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Roseville, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Sacramento, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
San Jose, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
San Jose, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Torrance, CA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Torrance, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Aurora, CO
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Norwich, CT
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Norwich, CT
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
mi
from
Viera, FL
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
mi
from
Viera, FL
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Dalton, GA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Dalton, GA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Marietta, GA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
mi
from
Tifton, GA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
mi
from
Tifton, GA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Woodstock, GA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Woodstock, GA
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Chicago, IL
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Fishers, IN
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Fishers, IN
Click here to add this to my saved trials
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated:  4/12/2016
Clinical Research Facility
mi
from
Dubuque, IA
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
An Immunogenicity, Safety, and Non-Interference Evaluation of Pediatric Vaccines Administered Concomitantly With Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) to Healthy Toddlers
Status: Enrolling
Updated: 4/12/2016
Clinical Research Facility
mi
from
Dubuque, IA
Click here to add this to my saved trials